Back to Agenda
ON DEMAND - Translating Frequently Collected Patient Experience Data into Meaningful Trial Endpoints
Session Chair(s)
Andrew Potter, PHD
Associate Director, Biostatics, United States
This forum will describe the challenges of determining clinically meaningful endpoints from frequently collected patient experience data. A panel will discuss considerations for translating this type of data into interpretable conclusions.
Learning Objective : Discuss issues regarding defining meaningful endpoints in light of more systematic and regular collection of patient experience data; Describe examples and identify considerations when formulating clinical trial endpoints.
Speaker(s)
Frequently Measured Endpoints: Focus on Actigraphy Data
Vice President, Product Intelligence and Positioning; Principal, eCOA Science, Signant Health , United Kingdom
Preliminary Considerations and Challenges When Formulating an Endpoint From Frequently Collected Patient-Reported Outcomes (PRO) Data
Mathematical Statistician, Office of Biostatistics, CDER, FDA, United States
Endpoint Development Utilizing Digital Health Technologies
Health Science Policy Analyst, OMP, CDER, FDA, United States
Panel Discussion
Associate Director, Biostatics, United States
Have an account?